杏林製薬の株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2022/08/26 | 1,771 | 1,782 | 1,765 | 1,769 | -2 | -0.1% | 33,700 |
| 2022/08/25 | 1,764 | 1,779 | 1,762 | 1,771 | +18 | +1% | 68,100 |
| 2022/08/24 | 1,746 | 1,761 | 1,742 | 1,753 | -20 | -1.1% | 95,200 |
| 2022/08/23 | 1,758 | 1,773 | 1,756 | 1,773 | +2 | +0.1% | 35,800 |
| 2022/08/22 | 1,744 | 1,772 | 1,742 | 1,771 | +14 | +0.8% | 93,900 |
| 2022/08/19 | 1,788 | 1,788 | 1,743 | 1,757 | -33 | -1.8% | 133,700 |
| 2022/08/18 | 1,800 | 1,800 | 1,786 | 1,790 | -9 | -0.5% | 38,600 |
| 2022/08/17 | 1,795 | 1,802 | 1,786 | 1,799 | +15 | +0.8% | 50,900 |
| 2022/08/16 | 1,782 | 1,785 | 1,771 | 1,784 | +3 | +0.2% | 33,700 |
| 2022/08/15 | 1,770 | 1,782 | 1,768 | 1,781 | +12 | +0.7% | 55,100 |
| 2022/08/12 | 1,760 | 1,788 | 1,758 | 1,769 | +20 | +1.1% | 96,600 |
| 2022/08/10 | 1,719 | 1,749 | 1,719 | 1,749 | +27 | +1.6% | 34,000 |
| 2022/08/09 | 1,758 | 1,758 | 1,722 | 1,722 | -30 | -1.7% | 50,500 |
| 2022/08/08 | 1,758 | 1,764 | 1,740 | 1,752 | -5 | -0.3% | 38,700 |
| 2022/08/05 | 1,746 | 1,767 | 1,746 | 1,757 | +34 | +2% | 105,800 |
| 2022/08/04 | 1,725 | 1,738 | 1,705 | 1,723 | +3 | +0.2% | 99,800 |
| 2022/08/03 | 1,773 | 1,773 | 1,715 | 1,720 | -57 | -3.2% | 120,900 |
| 2022/08/02 | 1,808 | 1,808 | 1,769 | 1,777 | -51 | -2.8% | 98,000 |
| 2022/08/01 | 1,810 | 1,828 | 1,798 | 1,828 | +22 | +1.2% | 57,000 |
| 2022/07/29 | 1,850 | 1,850 | 1,803 | 1,806 | -44 | -2.4% | 50,500 |
| 2022/07/28 | 1,842 | 1,859 | 1,823 | 1,850 | -4 | -0.2% | 68,900 |
| 2022/07/27 | 1,859 | 1,867 | 1,849 | 1,854 | -9 | -0.5% | 48,800 |
| 2022/07/26 | 1,873 | 1,878 | 1,858 | 1,863 | -21 | -1.1% | 31,300 |
| 2022/07/25 | 1,897 | 1,897 | 1,875 | 1,884 | +3 | +0.2% | 41,400 |
| 2022/07/22 | 1,890 | 1,892 | 1,880 | 1,881 | -7 | -0.4% | 54,300 |
| 2022/07/21 | 1,865 | 1,890 | 1,836 | 1,888 | +18 | +1% | 78,100 |
| 2022/07/20 | 1,859 | 1,874 | 1,845 | 1,870 | +22 | +1.2% | 94,200 |
| 2022/07/19 | 1,850 | 1,850 | 1,828 | 1,848 | -3 | -0.2% | 45,900 |
| 2022/07/15 | 1,847 | 1,862 | 1,843 | 1,851 | +13 | +0.7% | 76,400 |
| 2022/07/14 | 1,837 | 1,847 | 1,831 | 1,838 | -13 | -0.7% | 43,700 |
| 2022/07/13 | 1,834 | 1,852 | 1,833 | 1,851 | +10 | +0.5% | 66,100 |
| 2022/07/12 | 1,845 | 1,849 | 1,825 | 1,841 | -10 | -0.5% | 69,100 |
| 2022/07/11 | 1,819 | 1,859 | 1,805 | 1,851 | +51 | +2.8% | 113,500 |
| 2022/07/08 | 1,812 | 1,824 | 1,762 | 1,800 | -6 | -0.3% | 175,500 |
| 2022/07/07 | 1,821 | 1,825 | 1,803 | 1,806 | -1 | -0.1% | 136,700 |
| 2022/07/06 | 1,770 | 1,808 | 1,768 | 1,807 | +22 | +1.2% | 90,600 |
| 2022/07/05 | 1,791 | 1,795 | 1,776 | 1,785 | -8 | -0.4% | 67,100 |
| 2022/07/04 | 1,807 | 1,807 | 1,775 | 1,793 | +17 | +1% | 69,000 |
| 2022/07/01 | 1,774 | 1,800 | 1,762 | 1,776 | +2 | +0.1% | 73,600 |
| 2022/06/30 | 1,795 | 1,803 | 1,764 | 1,774 | -10 | -0.6% | 90,600 |
| 2022/06/29 | 1,781 | 1,792 | 1,769 | 1,784 | -11 | -0.6% | 219,800 |
| 2022/06/28 | 1,749 | 1,795 | 1,741 | 1,795 | +55 | +3.2% | 115,100 |
| 2022/06/27 | 1,758 | 1,758 | 1,725 | 1,740 | -2 | -0.1% | 82,300 |
| 2022/06/24 | 1,794 | 1,794 | 1,737 | 1,742 | -41 | -2.3% | 202,000 |
| 2022/06/23 | 1,752 | 1,788 | 1,752 | 1,783 | +39 | +2.2% | 199,600 |
| 2022/06/22 | 1,722 | 1,747 | 1,718 | 1,744 | +49 | +2.9% | 197,400 |
| 2022/06/21 | 1,676 | 1,700 | 1,673 | 1,695 | +31 | +1.9% | 138,300 |
| 2022/06/20 | 1,670 | 1,681 | 1,661 | 1,664 | +2 | +0.1% | 68,900 |
| 2022/06/17 | 1,648 | 1,672 | 1,645 | 1,662 | -1 | -0.1% | 96,300 |
| 2022/06/16 | 1,670 | 1,679 | 1,659 | 1,663 | -13 | -0.8% | 180,500 |
551～
600
件表示中 / 3586件
類似銘柄と比較する
現在ご覧いただいている「杏林製薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| 杏林製薬 | 149,900円 | +3.2% | +4.5% | 3.47% | 17.22倍 | 0.66倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
| ゼリア新薬 | 224,400円 | +13.6% | +29.2% | 2.05% | 11.64倍 | 1.12倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
| ネクセラファーマ | 113,200円 | +197.7% | - | 0.00% | 46.26倍 | 1.48倍 |
|
創薬ベンチャー老舗。買収で成長。英国の創薬事業に日本が柱の後期治験・製造販売事業加わる |
| ＪＣＲファーマ | 72,400円 | -3.7% | -36.7% | 2.76% | 23.84倍 | 1.56倍 |
|
ヒト成長ホルモン製剤が主力、バイオ後続品も成長。希少疾病のバイオ新薬開発にも取り組む |
| 栄研化 | 209,200円 | +0.4% | -8.4% | 2.53% | 27.65倍 | 1.57倍 |
|
臨床検査薬大手。便潜血検査試薬（ＦＩＴ）はシェア７割。尿検査（ウロ）、遺伝子検査も育成 |
市場注目の銘柄
チャート関連のコラム
